Robert Cawthorn - Chairman of the Board
Robert E. Cawthorn is an investor in Actelion and Chairman of the Board of Directors. Robert Cawthorn has a unique and successful track record of over 35 years in the pharmaceutical industry, which includes establishing start-ups and managing large pharmaceutical companies. Following his retirement as Chairman and CEO of Rhô-Poulenc-Rorer, Inc., he was a managing director of Global Health Care Partners, DLJ Merchant Banking. After 17 years as an executive with Pfizer International, he became the first president of Biogen and was active in creating the foundations for the future success of the company. He joined the Rorer Group in 1982 and, as Chairman and CEO, led the transformation of Rorer from a small, primarily over-the-counter pharmaceutical company into a major research-driven company, culminating in the merger that created Rhône-Poulenc-Rorer.

Werner Henrich - Chairman of the Board of Basilea Pharmaceutica
Werner Henrich was born 1943 and is a French citizen. He has an education as a chemist and European patent attorney. He worked for F. Hoffmann-La Roche Ltd. (“Roche”) in Basel for more than 30 years. Mr. Henrich held various positions at Roche including Head of Global Intellectual Property and Pharmaceutical Licensing for more than 12 years. He was also a member of the Roche Pharmaceutical Division Executive Board. In this function Mr. Henrich was responsible for intellectual property activities of all Roche divisions and for major pharmaceutical transactions including research collaborations, patent settlements, licensing-in and -out as well as product acquisitions. He retired from Roche in November 2003. Mr. Henrich has a wide experience in the pharmaceutical industry both with start-ups and large pharmaceutical companies. Mr. Henrich is Chairman of the board of Basilea Pharmaceutica Ltd. and a member of the board of directors of Actelion Ltd., Allschwil and Addex Pharmaceuticals Ltd., Geneva, Swiss biopharmaceutical companies listed on the SWX Swiss Exchange. He acts as a consultant for several biopharmaceutical companies on a part-time basis.

Armin Kessler - Armin M. Kessler served as Chief Operating Officer of Hoffmann-La Roche in Basel Switzerland from 1990 to 1995. Prior to being appointed COO, he held several senior positions at Hoffmann-La Roche, including head of the pharmaceutical and diagnostic divisions of the organization. Earlier positions in his career included Director of Pharmaceutical Marketing Worldwide for Sandoz (now Novartis) and President of Sandoz KK in Tokyo. He currently serves on the board of The Medicines Company, Gen_Probe and Spectrum Pharmaceuticals (formerly Neotherapeutics) and has served on the boards of Hoffmann-La Roche, Syntex and Genentech. He received a degree in Physics and Chemistry from Pretoria University in South Africa, a degree in Chemical Engineering from the University of Cape Town, South Africa, a Juris Doctorate from Seton Hall University, New Jersey, and Dr. h.c. in Business Administration from the University of Pretoria.

Jean Malo - Chief Investment Officer of Breeco Management L.P.
Jean Malo joined Breeco Management L.P., a Houston-based investment advisor, as a Senior Partner and Chief Investment Officer in 2000. He was Chief Investment Officer for Vaughan Nelson Scarborough and McCullough, a Houston-based affiliate of Metropolitan Life, managing $5 billion of assets between 1997 and 2000.
From 1989 to 1997, Mr. Malo managed both equity and fixed income portfolios for Daniel Breen and Company, an affiliate of Banque Indosuez (a French merchant bank), in Houston. From 1978 to 1989, he was a corporate banker for Banque Indosuez in Saudi Arabia, then in Houston, and finally in New York where he was in charge of fixed income derivatives sales. Between 1977 and 1978, he was a financial analyst at the French Embassy in Singapore.
Mr. Malo received an MBA from Essec, Paris France, in 1977. He is a Chartered Financial Analyst and a member of the Association for Investment Management and Research and the Houston Society of Financial Analysts.

Andre Mueller - Vice Chairman of the Board of Directors
With two degrees in Chemical Engineering and Business Administration from INSEAD, André Mueller started his career with CIBA Ltd and Sandoz (now Novartis) where he held a number of managerial positions in the strategic planning and finance divisions both at headquarters and in the US. After seven years with Sandoz, he moved to Biogen, becoming VP of Finance and Administration and then CFO. As CFO he was responsible for several financing rounds including Biogen's IPO. Four years later, he became a Founding Partner and Director of Investments for Genevest, the first Swiss venture capital organization.

Juhani Anttila  - Juhani Anttila was CEO of the Ascom Group between January 2003 and May 2004. As President and CEO of the Swisslog Group he served from 1996 to 2002. Between 1990 and 1995 he was Chairman of the Executive Board of Nokia (Deutschland) GmbH, Pforzheim. In 1985, he was appointed as Managing Director of Nokia GmbH, Zurich, responsible for various activities for the Nokia Group. Mr. Anttila studied law at the University of Helsinki, Finland before he became Managing Partner at CA Corporate Advisers, Zurich, in 1981.

Carl Feldbaum - Carl B. Feldbaum was president of the Biotechnology Industry Organization (BIO) in Washington, D.C. from its founding in 1993 to January 2005. Earlier roles concluded president and founder of the Palomar Corporation, a national security "think tank" in Washington, D.C.. He also served as assistant to the Secretary of Energy and as the Inspector General for defense intelligence in the U.S. Department of Defense. In 1979, he was awarded the Distinguished Civilian Service Medal from Defense Secretary Harold Brown. After receiving a bachelor's degree in Biology from Princeton University and a law degree from the University of Pennsylvania Law School, Mr. Feldbaum came to Washington D.C. in 1973 as an assistant special prosecutor for the Watergate special prosecution force.